Priya Sethumadhavan

Priya Sethumadhavan

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2024 in Data
Verified
Journal Article
Open access
PDF file
SKSepehr Golriz Khatami
Sepehr Golriz Khatami
ASAstghik Sargsyan
Astghik Sargsyan
MRMaria Francesca Russo
Maria Francesca Russo
DDDaniel Domingo
Daniel Domingo
AZAndrea Zaliani
Andrea Zaliani
AKAlpha Tom Kodamullil
Alpha Tom Kodamullil
Although hundreds of datasets have been published since the beginning of the coronavirus pandemic, there is a lack of centralized resources where these datasets are listed and harmonized to facilitate their applicability and uptake by predictive modeling approaches. Firstly, such a centralized resource provides information about data owners to researchers who are searching datasets to develop their predictive models. Secondly, the harmonization of the datasets supports simultaneously taking advantage of several similar datasets. This, in turn, does not only ease the imperative external validation of data-driven models but can also be used for virtual cohort generation, which helps to overcome data sharing impediments. Here, we present that the COVID-19 data catalogue is a repository that provides a landscape view of COVID-19 studies and datasets as a putative source to enable researchers to develop personalized COVID-19 predictive risk models. The COVID-19 data catalogue currently contains over 400 studies and their relevant information collected from a wide range of global sources such as global initiatives, clinical trial repositories, publications, and data repositories. Further, the curated content stored in this data catalogue is complemented by a web application, providing visualizations of these studies, including their references, relevant information such as measured variables, and the geographical locations of where these studies were performed. This resource is one of the first to capture, organize, and store studies, datasets, and metadata related to COVID-19 in a comprehensive repository. We believe that our work will facilitate future research and development of personalized predictive risk models for COVID-19.

10 August 2026 in Cellular and Molecular Neurobiology
Verified
Journal Article
Open access
PDF file
FHFeng He
Feng He
AMAndrea Martí-Sarrias
Andrea Martí-Sarrias
HGHeval Atas Guvenilir
Heval Atas Guvenilir
RSRenata Baptista Vieira de Sá
Renata Baptista Vieira de Sá
ASAdithya Sridhar
Adithya Sridhar
RKRejko Krüger
Rejko Krüger
Neurological complications are among typical clinical manifestations, both during the acute phase of SARS-CoV-2 infection and long-term post-acute COVID-19 sequelae, i.e., Long COVID. A growing body of evidence connects SARS-CoV-2 infection to systemic inflammation, peripheral immune dysregulation, functional alteration of the blood–brain barrier (BBB), neuroinflammatory processes, mitochondrial dysfunction and pathological protein aggregation, all of which are central to the pathogenesis of major neurodegenerative diseases. In this review, we discuss the converging shared underlying molecular mechanisms that link the ‘acute’ SARS-CoV-2 infection that often only lasts for days and ‘chronic’ neurodegenerative diseases that often take decades to develop. We further review human induced pluripotent stem cells (iPSCs)-derived brain organoid and BBB models for Parkinson’s disease (PD) and Alzheimer’s disease (AD) as well as artificial intelligence (AI)-facilitated knowledge graph methods that are used to hypothesize and validate the potential mechanistic links. We propose that besides the established links between viral infections and neurodegenerative or neuroinflammatory conditions, such as Epstein-Barr virus (EBV) in multiple sclerosis or herpes zoster in AD, SARS-CoV-2 infection might be another important factor driving the future burden of the most common neurodegenerative diseases. Graphical Abstract Schematic illustrating the potential link between the progression from SARS-CoV-2 infection and immune dysregulation to the development of Long COVID and eventually the subsequent onset of major neurodegenerative diseases (e.g., Parkinson's disease and Alzheimer's disease).

19 August 2025 in bioRxiv
Verified
Preprint
Open access
HGHeval Atas Guvenilir
Heval Atas Guvenilir
PSPriya Sethumadhavan
Priya Sethumadhavan
AKAbish Kaladharan
Abish Kaladharan
RSRenata Vieira de Sa
Renata Vieira de Sa
ASAdithya Sridhar
Adithya Sridhar
AKAlpha Tom Kodamullil
Alpha Tom Kodamullil
Summary: COVID-19 is increasingly recognized as a potential trigger or accelerator of neurodegenerative diseases such as Alzheimer’s and Parkinson’s. To systematically explore the putative molecular and clinical associations between them, we present CBM KG (Causal Biological Mechanisms Knowledge Graph)—a manually curated, comorbidity-centric resource developed within the EU-funded COMMUTE project. CBM KG integrates over 2,800 cause-and-effect or correlative relationships from 63 peer-reviewed publications, highlighting key mechanisms such as viral entry routes, blood-brain barrier alteration, microglial activation, neuroinflammation, and APOE ε4-associated susceptibility. Each relationship in the graph is fully traceable to its source evidence, ensuring transparency and reproducibility. Unlike general-purpose or single disease-focused knowledge graphs, CBM KG is specifically designed to represent causal biological mechanisms spanning both infectious and neurodegenerative processes. By encoding directional, cause-and-effect relationships, it supports the interpretation of clinical co-occurrences through plausible mechanistic links between overlapping disease pathways, offering high-resolution insights at both molecular and clinical levels. Availability and implementation: The BEL files, Neo4j database, and Cytoscape visualization files are publicly available at: https://github.com/SCAI-BIO/CBM-Comorbidity-KG .

10 March 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
FHFeng He
Feng He
AMAndrea Martí-Sarrias
Andrea Martí-Sarrias
HGHeval Atas Guvenilir
Heval Atas Guvenilir
RSRenata Vieira de Sá
Renata Vieira de Sá
ASAdithya Sridhar
Adithya Sridhar
RKRejko Krüger
Rejko Krüger
Background: Neurological complications are among typical clinical manifestations, both during the acute phase of SARS-CoV-2 infection and long-term post-acute COVID-19 sequelae, i.e., Long COVID. A growing body of evidence connects SARS-CoV-2 infection to systemic inflammation, peripheral immune dysregulation, blood-brain barrier (BBB) dysfunction, neuroinflammatory processes, mitochondrial dysfunction and pathological protein aggregation, all of which are central to the pathogenesis of major neurodegenerative diseases. Main Body: In this review, we discuss the converging shared underlying molecular mechanisms that link the ‘acute’ SARS-CoV-2 infection that often only lasts for days and ‘chronic’ neurodegenerative diseases that often take decades to develop. We further review human induced pluripotent stem cells (iPSCs)-derived brain organoid and BBB models for Parkinson’s disease (PD) and Alzheimer’s disease (AD) as well as artificial intelligence (AI)-facilitated knowledge graph methods that are used to hypothesize, discover and validate the potential mechanistic links. Conclusions: We suggest that besides the established links between viral infections and neurodegenerative or neuroinflammatory conditions, such as Epstein-Barr virus (EBV) in multiple sclerosis or herpes zoster in AD, SARS-CoV-2 infection is another important factor defining the future burden of the most common neurodegenerative diseases.